These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Kohsaka S; Takahashi K; Wang L; Tanino M; Kimura T; Nishihara H; Tanaka S Cancer Lett; 2013 Apr; 331(1):68-75. PubMed ID: 23246370 [TBL] [Abstract][Full Text] [Related]
23. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
24. Dual-targeted delivery of temozolomide by multi-responsive nanoplatform via tumor microenvironment modulation for overcoming drug resistance to treat glioblastoma. Chen X; Zheng Y; Zhang Q; Chen Q; Chen Z; Wu D J Nanobiotechnology; 2024 May; 22(1):264. PubMed ID: 38760771 [TBL] [Abstract][Full Text] [Related]
25. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. Yang B; Ma YB; Chu SH Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041 [TBL] [Abstract][Full Text] [Related]
26. A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia. Musah-Eroje A; Watson S J Neurooncol; 2019 Apr; 142(2):231-240. PubMed ID: 30694423 [TBL] [Abstract][Full Text] [Related]
27. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma. Chai Y; Wang C; Liu W; Fan Y; Zhang Y J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818 [TBL] [Abstract][Full Text] [Related]
28. Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization. Garnier D; Meehan B; Kislinger T; Daniel P; Sinha A; Abdulkarim B; Nakano I; Rak J Neuro Oncol; 2018 Jan; 20(2):236-248. PubMed ID: 29016925 [TBL] [Abstract][Full Text] [Related]
29. Down-regulation of MDR1 by Ad-DKK3 via Akt/NFκB pathways augments the anti-tumor effect of temozolomide in glioblastoma cells and a murine xenograft model. Fujihara T; Mizobuchi Y; Nakajima K; Kageji T; Matsuzaki K; Kitazato KT; Otsuka R; Hara K; Mure H; Okazaki T; Kuwayama K; Nagahiro S; Takagi Y J Neurooncol; 2018 Sep; 139(2):323-332. PubMed ID: 29779087 [TBL] [Abstract][Full Text] [Related]
30. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma. Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238 [TBL] [Abstract][Full Text] [Related]
31. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
32. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients. Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940 [TBL] [Abstract][Full Text] [Related]
33. Targeting NFE2L2, a transcription factor upstream of MMP-2: A potential therapeutic strategy for temozolomide resistant glioblastoma. Rajesh Y; Biswas A; Kumar U; Das S; Banerjee I; Banik P; Bharti R; Nayak S; Ghosh SK; Mandal M Biochem Pharmacol; 2019 Jun; 164():1-16. PubMed ID: 30885764 [TBL] [Abstract][Full Text] [Related]
34. Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma. Shang C; Tang W; Pan C; Hu X; Hong Y Cancer Chemother Pharmacol; 2018 Apr; 81(4):671-678. PubMed ID: 29397407 [TBL] [Abstract][Full Text] [Related]
35. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
36. Involvement of Intracellular Cholesterol in Temozolomide-Induced Glioblastoma Cell Death. Yamamoto Y; Sasaki N; Kumagai K; Takeuchi S; Toyooka T; Otani N; Wada K; Narita Y; Ichimura K; Namba H; Mori K; Tomiyama A Neurol Med Chir (Tokyo); 2018 Jul; 58(7):296-302. PubMed ID: 29899179 [TBL] [Abstract][Full Text] [Related]
37. Newcastle disease virus enhances the growth-inhibiting and proapoptotic effects of temozolomide on glioblastoma cells in vitro and in vivo. Bai Y; Chen Y; Hong X; Liu X; Su X; Li S; Dong X; Zhao G; Li Y Sci Rep; 2018 Jul; 8(1):11470. PubMed ID: 30065314 [TBL] [Abstract][Full Text] [Related]
38. Establishment of a Novel Temozolomide Resistant Subline of Glioblastoma Multiforme Cells and Comparative Transcriptome Analysis With Parental Cells. Ha HA; Yang JS; Tsai FJ; Li CW; Cheng YD; Li J; Hour MJ; Chiu YJ Anticancer Res; 2021 May; 41(5):2333-2347. PubMed ID: 33952458 [TBL] [Abstract][Full Text] [Related]
39. miR-128 and miR-149 enhance the chemosensitivity of temozolomide by Rap1B-mediated cytoskeletal remodeling in glioblastoma. She X; Yu Z; Cui Y; Lei Q; Wang Z; Xu G; Xiang J; Wu M; Li G Oncol Rep; 2014 Sep; 32(3):957-64. PubMed ID: 25017996 [TBL] [Abstract][Full Text] [Related]
40. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells. Wang HH; Chang TY; Lin WC; Wei KC; Shin JW Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]